Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1919-1929

  Campiani, Giuseppe ^a   Fattorusso, Caterina ^a,b   Butini, Stefania ^a   Gaeta, Alessandra ^a   Agnusdei, Marianna ^a   Gemma, Sandra ^a   Persico, Marco ^a,b   Catalanotti, Bruno ^a,b   Savini, Luisa ^a   Nacci, Vito ^a   Novellino, Ettore ^a,b   Holloway, Harold W ^c   Greig, Nigel H ^c   Belinskaya, Tatyana ^d   Fedorko, James M ^d   Saxena, Ashima ^d  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; N METHYL N'(1,2,3,4 TETRAHYDROACRIDIN 9 YL)N[3 (1,2,3,4 TETRAHYDROACRIDIN 9 YLSULFANYL)PROPYL] 1,3 PROPANEDIAMINE; N METHYL N'(1,2,3,4 TETRAHYDROACRIDIN 9 YL)N[4 (1,2,3,4 TETRAHYDROACRIDIN 9 YLSULFANYL)BUTYL] 1,3 PROPANEDIAMINE; N(1,2,3,4 TETRAHYDROACRIDIN 9 YL) 9 [(1,2,3,4 TETRAHYDRO 9 YL)THIO]NONAN 1 AMINE; N(1,2,3,4 TETRAHYDROACRIDIN 9 YL)N[8 (1,2,3,4 TETRAHYDROACRIDIN 9 YL)OCT 1 YL]AMINE; N,N BIS[3 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PROPYL]N ALLYLAMINE; N,N BIS[3 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PROPYL]N ETHYLAMINE; N,N BIS[3 [(1,2,3,4 TETRAHYDROACRIDIN 9 YL)AMINO]PROPYL]N HYDROXYETHYLAMINE; N[3 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)PROPYL]N'[3 (1,2,3,4 TETRAHYDROACRIDIN 9 YLSULFANYL)PROPYL]ACETAMIDE; N[3 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)PROPYL]N'[4 (1,2,3,4 TETRAHYDROACRIDIN 9 YLSULFANYL)BUTYL]ACETAMIDE; NITROGEN; SULFUR; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ATOM; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; MOLECULAR MODEL; MOLECULAR PROBE; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; ACRIDINES; BINDING SITES; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR PROBES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20144367586     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049510k     Document Type: Article

References (21)

1. Mesulam, M. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In Cholinesterase and cholinesterase inhibitors; Giacobini, E., Ed.; Martin Donitz: London, 2000; pp 121-137.
2. Giacobini, E. Cholinergic functions in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18, S1-S5, and references therein.
3. Gentry, M. K.; Doctor, B. P. In Cholinesterases: structure, function, mechanism, genetics, and cell biology; Massoulie, J., Bacou, F., Barnard, E. A., Chatonnet, A., Doctor, B. P., Eds.; American Chemical Society: Washington, DC, 1991; pp 394-398.
4. Saxena, A.; Redman, A. M. G.; Jiang, X.; Lockridge, O.; Doctor, B. P. Differences in Active Site Gorge Dimension of Cholinesterases Revealed by Binding of Inhibitors to Human Butyrylcholinesterase. Biochemistry 1997, 36, 14642-14651.
5. Mack, A.; Robitzki, A. The Key Role of Butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5′-butyrylcholinesterase- DNA study. Prog. Neurobiol. 2000, 60, 607-628 and references therein.
6. Greig, N. H.; Utsuki, T.; Yu, Q.-S.; Zhu, X.; Holloway, H. W.; Perry, T.; Lee, B.; Ingram, D. K.; Lahiri, D. K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17, 1-6.
7. Mesulam, M. M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience 2002, 110, 627-639.
8. Yu, Q.-S.; Holloway, H. W.; Utsuki, T.; Brossi, A.; Greig, N. H. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. 1999, 42, 1855-1861.
9. Giacobini, E.; Spiegel, R.; Enz, A.; Veroff, A. E.; Cutler, N. R. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J. Neural Transm. 2002, 109, 1053-1065.
10. Savini, L.; Campiani, G.; Gaeta, A.; Pellerano, C.; Fattorusso, C.; Chiasserini, L.; Fedorko, J. M.; Saxena, A. Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg. Med. Chem. Lett. 2001, 11, 1779-1782.
11. Savini, L.; Gaeta, A.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors. J. Med. Chem. 2003, 46, 1-4.
12. Carlier, P. R.; Chow, E. S.-H.; Han, Y.; Liu, J.; El Yazal, J.; Pang, Y.-P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. J. Med. Chem. 1999, 42, 4225-4231 and references therein.
13. Geula, C.; Mesulam, M. M. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1995, 9 (Suppl. 2), 23-28.
14. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001, 40, 10447-10457.
15. Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 1988, 4, 31-47.
16. Senderowitz, H.; Guarnieri, F.; Still, W. C. A Smart Monte Carlo Technique for Free Energy Simulations of Multiconformational Molecules. Direct Calculations of the Conformational Populations of Organic Molecules. J. Am. Chem. Soc. 1995, 117, 8211-8219.
17. Ding, H. Q.; Karasawa, N.; Goddard, W. A., III. Atomic level simulations on a million particles: The cell multipole method for Coulomb and London non-bond interactions. J. Chem. Phys. 1992, 97, 4309-4315.
18. Singh, J.; Thornton, J. M. SIRIUS. An automated method for the analysis of the preferred packing arrangements between protein groups. J. Mol. Biol. 1990, 211, 595-615.
19. Hunter, C. A.; Lawson, K. R.; Perkins, J.; Urch, C. J. Aromatic interactions. J. Chem. Soc., Perkin Trans. 1 2001, 2, 651-669.
20. Cubero, E.; Luque, J. F.; Orozco, M. Is polarization important in cation-π interactions? Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5976-5980.
21. Kim, K. S.; Tarakeshwar, P.; Yong Lee, J. Molecular clusters of π-Systems: Theoretical Studies of Structures, Spectra, and Origin of Interaction Energies. Chem. Rev. 2000, 100, 4145-4185.